– ATTORNEY NEWSLETTER –
Amgen, Inc., a California-based biotechnology company, agrees to pay a $2.9 million settlement after allegations of marketing their products to patients who did not fit the approved labeling by the Food & Drug Administration. The product in subject, Aranesp, is approved for usage of patients who are suffering from “anemia associated with renal failure.” However, after investigation, it found that Aranesp was sold to long-term care pharmacy providers with illegal kickbacks based on the sales performance with Aranesp products. As a result, pharmacies were strongly marketed to patients without the approved FDA patient symptoms “anemia associated with renal failure.” An Amgen employee brought evidence and suit upon Amgen, Inc. filing false documentation in order to conceal the money earned from the kickbacks out of the government’s eyes. The Amgen employee, the whistleblower under the qui tam or whistleblower provision under the False Claims Act, is entitled to a share of the government’s proceedings in the settlement.
This agreement by Amgen, Inc. shows a new push in holding drug manufacturers accountable for illegal business practices. Making strides toward big drug manufacturers understanding their role in drug use is crucial for the safety of our loved ones, especially those under long-term care, where products are highly marketed for the health of those living with chronic illness or disability.
If you or a loved one are concerned about drug usage advised by a pharmacy, Evans Law Firm, Inc. recommends contacting an experienced elder abuse and false claims attorney. Contact Evans Law Firm, Inc. today at 415-441-8669 or e-mail us at info@evanslaw.com for a free and confidential consultation.
